key: cord-0769484-z1pc9nh1
authors: Kang, Na‐Young C.; Hsiao, Jennifer; Shi, Vivian; Naik, Haley B.; Lowes, Michelle A.; Alavi, Afsaneh
title: Remote management of hidradenitis suppurativa in a pandemic era of COVID‐19
date: 2020-06-23
journal: Int J Dermatol
DOI: 10.1111/ijd.15022
sha: 223b1afd010e57812d91ddb149ad39e46d0d74f1
doc_id: 769484
cord_uid: z1pc9nh1

nan

Optimizing teledermatology visits: To avoid emergency department/hospital visits and COVID-19 exposure, teledermatology has replaced most in-person consultations, posing unique challenges for HS management. For example, patients may feel reluctant and uncomfortable with exposing intertriginous (especially genital) areas via videoconferencing. Thus, we recommend patients send photos of private areas instead prior to their virtual appointment. To mitigate risks of data breach, photos can be sent via secure email or patient portal, which can then be directly uploaded onto their electronic medical record accessible to authorized individuals only. Furthermore, physical access to computers can be limited by locking workstations. For less sensitive body sites amenable to examination via videoconference, patients should be instructed to remove dressings in advance to minimize pain from rushed removals, and the same privacy standards used for in-person visits should be maintained during videoconferencing (e.g., private consultation room). Since providers are unable to palpate fluctuant lesions that may require specific treatment, patients may be asked to apply pressure to lesions on camera. Finally, providers should consider providing management strategies and tips on when to arrange teledermatology to triage whether in-person visits are required. Overall, even with optimized teledermatology, patients with HS may still require in-person care (e.g., surgery), making HS different from other chronic inflammatory dermatoses (e.g., atopic dermatitis or psoriasis) that do not involve procedures and can be managed remotely.

Minimizing HS flares: Experts recommend educating patients on flare prevention strategies (diet alteration and trigger avoidance), having short-term antibiotic prescriptions available, and having medications delivered to patients. At-home management for HS flares includes warm compresses, benzoyl peroxide wash, topical anesthetics, resorcinol or dapsone 5% gel, and over-the-counter analgesics. Currently, deroofing, local anesthetic procedures, and intralesional injections may be offered, however, many HS surgeries have been postponed.

Treatment considerations for HS: Some biologics are associated with a slight increased risk of nasopharyngitis and upper respiratory tract infections (Fig. 1 In conclusion, patients with HS require special strategies in remote care. Providers should consider initiating virtual support groups for patients experiencing profound psychosocial suffering. 11 Furthermore, the decision to continue treatment should be determined on a case-by-case basis, taking into consideration patients' exposure risks for SARS-CoV-2, HS severity, risk of flaring, comorbidities, drug mechanism of action, and patients' response to retreatment. More data are needed to guide HS management in the context of COVID-19, and we encourage practitioners to contribute to the following registries: 

People who are at higher risk for severe illness

Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: safety considerations

Kineret â (anakinra) for injection, for subcutaneous use

Tremfya (guselkumab) injection, for subcutaneous use

Remicade (infliximab) lyophilized concentrate for injection, for intravenous use

Cosentyx TM (secukinumab) injection, for subcutaneous use

Stelara â (ustekinumab) injection, for subcutaneous or intravenous use

Malignancy and infection risk during adalimumab therapy in hidradenitis suppurativa

Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study

Reninangiotensin-aldosterone system inhibitors in patients with Covid-19

The role of virtual support groups for patients with hidradenitis suppurativa during the COVID-19 pandemic